Evidence map›Paper›PMID 33855079›Full record

ArticleBioMed research international2021

The Potential Safe Antifibrotic Effect of Stem Cell Conditioned Medium and Nilotinib Combined Therapy by Selective Elimination of Rat Activated HSCs.

Ahmed Nabil, Koichiro Uto, Faten Zahran, Reham Soliman, Ayman A Hassan, Mohamed M Elshemy, Islam S Ali, Mitsuhiro Ebara, Gamal Shiha

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Ahmed NabilResearch Center for Functional Materials, National Institute for Materials Science (NIMS), 1-1Namiki, Tsukuba, Ibaraki 305-0044, Japan.ORCID https://orcid.org/0000-0002-5617-4726
Koichiro UtoResearch Center for Functional Materials, National Institute for Materials Science (NIMS), 1-1Namiki, Tsukuba, Ibaraki 305-0044, Japan.ORCID https://orcid.org/0000-0001-7091-0585
Faten ZahranBiochemistry Department, Faculty of Science, Zagazig University, Egypt.
Reham SolimanEgyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt.
Ayman A HassanEgyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt.
Mohamed M ElshemyFaculty of Science, Menoufia University, Menoufia, Egypt.ORCID https://orcid.org/0000-0002-6279-7559
Islam S AliDelta University for Science and Technology, Egypt.
Mitsuhiro EbaraResearch Center for Functional Materials, National Institute for Materials Science (NIMS), 1-1Namiki, Tsukuba, Ibaraki 305-0044, Japan.ORCID https://orcid.org/0000-0002-7906-0350
Gamal ShihaEgyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt.ORCID https://orcid.org/0000-0002-9338-8854
Mansoura University Hospital · EGBeni-Suef University · EGDelta University for Science and Technology · EGMansoura University · EGMenoufia University · EGNational Institute for Materials Science · JPUniversity of Tsukuba · JPZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic fibrosis is a progressive disease with serious clinical complications that arise from abnormal propagation and activation of multiple inflammatory pathways. Nilotinib is an oral tyrosine kinase inhibitor with antifibrotic activity. Mesenchymal stem cells (MSCs) are blank cells and can differentiate into specific cell types. They have the potential to repair and regenerate cells. MSCs have a special paracrine fashion where they produce special exosomes, microvesicles, and cytokines like IL-6, transforming growth factor-beta (TGF-

Indexed as

AnimalsApoptosisCells, CulturedCell SurvivalCollagenCombined Modality TherapyCulture Media, ConditionedCytochromes cDNAHepatic Stellate CellsInhibitory Concentration 50Liver CirrhosisMaleMesenchymal Stem CellsModels, BiologicalOxidative StressCollagenCulture Media, ConditionedCytochromes cDNAnilotinibPyrimidinesReactive Oxygen SpeciesTumor Suppressor Protein p53

Identifiers

PMID33855079
PMCPMC8021473
OpenAlexW3144425032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.